Norway's Vistin Pharma Q3 profit falls
Norway's Vistin Pharma Q3 profit falls
Overview
Norway pharmaceutical firm's Q3 revenue was flat yr/yr as currency strength offset volume growth
Q3 EBITDA and net profit declined compared to last year
Company declared additional NOK 0.50/share cash dividend for Q4
Outlook
Company continues to focus on sales volume growth and onboarding new customer volume in 2026
Company to pay additional NOK 0.50 per share cash dividend in Q4 2026
Result Drivers
VOLUME GROWTH OFFSET BY CURRENCY - Co said higher sales volumes were offset by a stronger NOK against EUR, impacting revenue in local currency
NEW CUSTOMER VOLUME - Co said onboarding new customer volume helped increase sales volume and utilize manufacturing capacity
Company press release: ID:nGNE2z0Jz8
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue |
| NOK 108.40 mln |
|
Q3 Net Income |
| NOK 11 mln |
|
Q3 EBITDA |
| NOK 19 mln |
|
Reuters Recommended Reads
Oct 27 - Pharming Group Q3 revenue rises on US demand; tightens guidance
Oct 28 - GSK pipeline doubts, vaccine underperformance overshadow sales beat
Oct 28 - Generic drugmaker Sandoz cuts sales outlook, shares fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)